Methods for actionable gene fusion detection in lung cancer: now and in the future

Cancer Statistics, 2021

(2021) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

RNA-Based Assay for Next-Generation Sequencing of Clinically Relevant Gene Fusions in Non-Small Cell Lung Cancer

(2021) Caterina De Luca et al.   Cancers

Genomic profiling in non-small-cell lung cancer in young patients. A systematic review

(2021) D. Viñal et al.   ESMO Open

Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study

(2021) Justin F Gainor et al.   LANCET ONCOLOGY

Attenuated isolated 3’ signal: A highly challenging therapy relevant ALK FISH pattern in NSCLC

(2020) Gábor Smuk et al.   LUNG CANCER

Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer

(2020) Alexander Drilon et al.   NEW ENGLAND JOURNAL OF MEDICINE

First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer

(2020) Alice T. Shaw et al.   NEW ENGLAND JOURNAL OF MEDICINE

Molecular Profile of Advanced Non-Small Cell Lung Cancers in Octogenarians: The Door to Precision Medicine in Elderly Patients

(2019) Caterina Fumagalli et al.   Journal of Clinical Medicine

Efficient ten-gene analysis of NSCLC tissue samples by next-generation sequencing

(2019) Xiuhuan Ji et al.   PATHOLOGY RESEARCH AND PRACTICE

Clinicopathological Features of ALK Expression in 9889 Cases of Non-small-Cell Lung Cancer and Genomic Rearrangements Identified by Capture-Based Next-Generation Sequencing: A Chinese Retrospective Analysis

(2019) Ruiying Zhao et al.   Molecular Diagnosis & Therapy

A Patient With Lung Adenocarcinoma With BRAF Gene Fusion and Response to Vemurafenib

(2019) You-cai Zhu et al.   Clinical Lung Cancer

Next-generation Sequencing for ALK and ROS1 Rearrangement Detection in Patients With Non–small-cell Lung Cancer: Implications of FISH-positive Patterns

(2019) Sergi Clavé et al.   Clinical Lung Cancer

Consistency and reproducibility of next‐generation sequencing in cytopathology: A second worldwide ring trial study on improved cytological molecular reference specimens

(2019) Pasquale Pisapia et al.   CANCER CYTOPATHOLOGY

Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–small Cell Lung Cancer

(2019) Natasha B. Leighl et al.   CLINICAL CANCER RESEARCH

Detection of NRG1 Gene Fusions in Solid Tumors

(2019) Sushma Jonna et al.   CLINICAL CANCER RESEARCH

Testing algorithm for identification of patients with TRK fusion cancer

(2019) Frédérique Penault-Llorca et al.   JOURNAL OF CLINICAL PATHOLOGY

Comparison of ALK detection by FISH, IHC and NGS to predict benefit from crizotinib in advanced non-small-cell lung cancer

(2019) Chen Lin et al.   LUNG CANCER

MicroRNA profiling in serous cavity specimens: Diagnostic challenges and new opportunities

(2019) Lorenzo Nicolè et al.   CANCER CYTOPATHOLOGY

RET fusions in solid tumors

(2019) Andrew Y. Li et al.   CANCER TREATMENT REVIEWS

Amplicon-based next-generation sequencing of plasma cell-free DNA for detection of driver and resistance mutations in advanced non-small cell lung cancer

(2018) N Guibert et al.   ANNALS OF ONCOLOGY

Analysis of Fusion Genes by NanoString System: A Role in Lung Cytology?

(2018) Greta Alì et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology

(2018) Neal I. Lindeman et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials

(2018) D. Ross Camidge et al.   JOURNAL OF CLINICAL ONCOLOGY

Evaluation of NGS and RT-PCR Methods for ALK Rearrangement in European NSCLC Patients: Results from the European Thoracic Oncology Platform Lungscape Project

(2018) Igor Letovanec et al.   Journal of Thoracic Oncology

Comparison of molecular testing modalities for detection of ROS1 rearrangements in a cohort of positive patient samples

(2018) Kurtis D. Davies et al.   Journal of Thoracic Oncology

Characteristics and Outcome of ROS1 -Positive Non–Small Cell Lung Cancer Patients in Routine Clinical Practice

(2018) Sehhoon Park et al.   Journal of Thoracic Oncology

PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project

(2018) Ming Sound Tsao et al.   Journal of Thoracic Oncology

ALK fusion variants detection by targeted RNA-next generation sequencing and clinical responses to crizotinib in ALK-positive non-small cell lung cancer

(2018) Anne McLeer-Florin et al.   LUNG CANCER

Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children

(2018) Alexander Drilon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer

(2018) Jean-Charles Soria et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeted next-generation-sequencing for reliable detection of targetable rearrangements in lung adenocarcinoma—a single center retrospective study

(2018) Nadezda P. Velizheva et al.   PATHOLOGY RESEARCH AND PRACTICE

Response to ERBB3-Directed Targeted Therapy in NRG1 -Rearranged Cancers

(2018) Alexander Drilon et al.   Cancer Discovery

Frequent NRG1 fusions in Caucasian pulmonary mucinous adenocarcinoma predicted by Phospho-ErbB3 expression

(2018) Domenico Trombetta et al.   Oncotarget

ALK- rearrangement in non-small-cell lung cancer (NSCLC)

(2018) Xue Du et al.   Thoracic Cancer

Simultaneous detection of lung fusions using a multiplex RT-PCR next generation sequencing-based approach: a multi-institutional research study

(2018) Cecily P. Vaughn et al.   BMC CANCER

Entrectinib Effective across NTRK Fusion–Positive Cancers

(2018)   Cancer Discovery

Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non–Small Cell Lung Cancer

(2018) Charu Aggarwal et al.   JAMA Oncology

Discordance between FISH, IHC, and NGS Analysis of ALK Status in Advanced Non–Small Cell Lung Cancer (NSCLC): a Brief Report of 7 Cases

(2018) Anna Scattone et al.   Translational Oncology

Multiplex digital colour-coded barcode technology on RNA extracted from routine cytological samples of patients with non-small cell lung cancer: pilot study

(2017) Roberta Sgariglia et al.   JOURNAL OF CLINICAL PATHOLOGY

ALK and NRG1 Fusions Coexist in a Patient with Signet Ring Cell Lung Adenocarcinoma

(2017) Lucia Anna Muscarella et al.   Journal of Thoracic Oncology

Lonely Driver ROS1

(2017) Spasenija Savic et al.   Journal of Thoracic Oncology

Durable Response to Afatinib in Lung Adenocarcinoma Harboring NRG1 Gene Fusions

(2017) Nathan D. Gay et al.   Journal of Thoracic Oncology

Recent Advances in Targeting ROS1 in Lung Cancer

(2017) Jessica J. Lin et al.   Journal of Thoracic Oncology

PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project

(2017) Fred R. Hirsch et al.   Journal of Thoracic Oncology

ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non–Small Cell Lung Cancer

(2017) Jessica J. Lin et al.   Journal of Thoracic Oncology

First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study

(2017) Jean-Charles Soria et al.   LANCET

Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial

(2017) Toyoaki Hida et al.   LANCET

Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance

(2017) Alison M. Schram et al.   Nature Reviews Clinical Oncology

Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer

(2017) Solange Peters et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)

(2017) Alexander Drilon et al.   Cancer Discovery

Clinical framework for next generation sequencing based analysis of treatment predictive mutations and multiplexed gene fusion detection in non-small cell lung cancer

(2017) Kajsa Ericson Lindquist et al.   Oncotarget

Detection of ALK fusion transcripts in FFPE lung cancer samples by NanoString technology

(2017) Adriane F. Evangelista et al.   BMC Pulmonary Medicine

Multiplexed transcriptome analysis to detect ALK, ROS1 and RET rearrangements in lung cancer

(2017) Toni-Maree Rogers et al.   Scientific Reports

Detection of known and novel ALK fusion transcripts in lung cancer patients using next-generation sequencing approaches

(2017) Julie A. Vendrell et al.   Scientific Reports

Profile of Ventana ALK (D5F3) companion diagnostic assay for non-small-cell lung carcinomas

(2016) Esther Conde et al.   EXPERT REVIEW OF MOLECULAR DIAGNOSTICS

Cabozantinib in patients with advanced RET -rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial

(2016) Alexander Drilon et al.   LANCET ONCOLOGY

Clinicopathologic characteristics, genetic variability and therapeutic options of RET rearrangements patients in lung adenocarcinoma

(2016) Zhengbo Song et al.   LUNG CANCER

Validation of a new algorithm for a quick and easy RT-PCR-based ALK test in a large series of lung adenocarcinomas: Comparison with FISH, immunohistochemistry and next generation sequencing assays

(2016) Antonio Marchetti et al.   LUNG CANCER

Testing for ROS1 in non-small cell lung cancer: a review with recommendations

(2016) Lukas Bubendorf et al.   VIRCHOWS ARCHIV

Oncogenic function and clinical implications of SLC3A2-NRG1 fusion in invasive mucinous adenocarcinoma of the lung

(2016) Dong Hoon Shin et al.   Oncotarget

Advanced lung adenocarcinomas with ROS1-rearrangement frequently show hepatoid cell

(2016) Jing Zhao et al.   Oncotarget

ALK FISH patterns and the detection of ALK fusions by next generation sequencing in lung adenocarcinoma

(2016) Sanja Dacic et al.   Oncotarget

MicroRNA expression profiles and clinicopathological implications in lung adenocarcinoma according to EGFR, KRAS, and ALK status

(2016) Hyojin Kim et al.   Oncotarget

Challenges and opportunities of next-generation sequencing: a cytopathologist's perspective

(2015) E. Vigliar et al.   CYTOPATHOLOGY

The distribution ofBRAFgene fusions in solid tumors and response to targeted therapy

(2015) Jeffrey S. Ross et al.   INTERNATIONAL JOURNAL OF CANCER

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

(2015) James Chih-Hsin Yang et al.   LANCET ONCOLOGY

microRNA classifiers are powerful diagnostic/prognostic tools inALK-,EGFR-, andKRAS-driven lung cancers

(2015) Pierluigi Gasparini et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Oncogenic fusion protein EWS-FLI1 is a network hub that regulates alternative splicing

(2015) Saravana P. Selvanathan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

TRK Inhibitor Shows Early Promise

(2015)   Cancer Discovery

Common Oncogene Mutations and Novel SND1-BRAF Transcript Fusion in Lung Adenocarcinoma from Never Smokers

(2015) Jin Sung Jang et al.   Scientific Reports

Clinicopathological characteristics and outcomes ofROS1-rearranged patients with lung adenocarcinoma withoutEGFR,KRASmutations andALKrearrangements

(2015) Shafei Wu et al.   Thoracic Cancer

Landscape of gene fusions in epithelial cancers: seq and ye shall find

(2015) Chandan Kumar-Sinha et al.   Genome Medicine

A Single-Tube Multiplexed Assay for Detecting ALK, ROS1, and RET Fusions in Lung Cancer

(2014) Maruja E. Lira et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: A comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features

(2014) Yunjian Pan et al.   LUNG CANCER

Comprehensive analysis of RET and ROS1 rearrangement in lung adenocarcinoma

(2014) Seung Eun Lee et al.   MODERN PATHOLOGY

First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer

(2014) Benjamin J. Solomon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer

(2014) Alice T. Shaw et al.   NEW ENGLAND JOURNAL OF MEDICINE

Transcriptome meta-analysis of lung cancer reveals recurrent aberrations in NRG1 and Hippo pathway genes

(2014) Saravana M. Dhanasekaran et al.   Nature Communications

The landscape of kinase fusions in cancer

(2014) Nicolas Stransky et al.   Nature Communications

CD74-NRG1 Fusions in Lung Adenocarcinoma

(2014) L. Fernandez-Cuesta et al.   Cancer Discovery

ROS1 Immunohistochemistry for Detection of ROS1-Rearranged Lung Adenocarcinomas

(2013) Lynette M. Sholl et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing

(2013) Garrett M Frampton et al.   NATURE BIOTECHNOLOGY

Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer

(2013) Aria Vaishnavi et al.   NATURE MEDICINE

Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer

(2013) Alice T. Shaw et al.   NEW ENGLAND JOURNAL OF MEDICINE

Detection of MicroRNAs in Archival Cytology Urine Smears

(2013) Francesca Simonato et al.   PLoS One

Cancer Genome Landscapes

(2013) B. Vogelstein et al.   SCIENCE

Multiplexed Gene Expression and Fusion Transcript Analysis to Detect ALK Fusions in Lung Cancer

(2012) Maruja E. Lira et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

(2012) Rafael Rosell et al.   LANCET ONCOLOGY

Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies

(2012) Doron Lipson et al.   NATURE MEDICINE

KIF5B-RET fusions in lung adenocarcinoma

(2012) Takashi Kohno et al.   NATURE MEDICINE

Role and Relevance of TrkB Mutations and Expression in Non-Small Cell Lung Cancer

(2011) T. Harada et al.   CLINICAL CANCER RESEARCH

An integrated semiconductor device enabling non-optical genome sequencing

(2011) Jonathan M. Rothberg et al.   NATURE

Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

(2010) Eunice L. Kwak et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeted next-generation sequencing of DNA regions proximal to a conserved GXGXXG signaling motif enables systematic discovery of tyrosine kinase fusions in cancer

(2010) Juliann Chmielecki et al.   NUCLEIC ACIDS RESEARCH

Chromosomal and genomic changes in lung cancer

(2010) Marileila Varella-Garcia   Cell Adhesion & Migration

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

(2009) Tony S. Mok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Frequent mutations in the neurotrophic tyrosine receptor kinase gene family in large cell neuroendocrine carcinoma of the lung

(2008) Antonio Marchetti et al.   HUMAN MUTATION

EWS/FLI Mediates Transcriptional Repression via NKX2.2 during Oncogenic Transformation in Ewing's Sarcoma

(2008) Leah A. Owen et al.   PLoS One